Professional Documents
Culture Documents
GOALS
Appreciation of history of Hypoplastic Left Heart Syndrome. Basic anatomy & physiology. Understand the LOGIC behind the management of HLHS (& single ventricle lesions in general).
History of HLHS
First described by Maurice Lev in 1952. Term used by Noonan & Nadas in 1958. Options offered:
Comfort care Staged palliative repair, i.e. Norwood procedure
First successful 3-stage completion in 1983 (after multiple surgeries from 1979).
Cardiac transplant
First successful cardiac transplant: Bailey, Nov. 1985
Anatomy
HLHS Epidemiology
Low incidence of 1.6 to 3.6 per 10,000 live births, BUT causes 23% or cardiac deaths during 1st week of life and 15% during the 1st month of life. Makes up about 2-4% of congenital heart disease. More commonly males (55% to 67%). With ONE affected child, recurrence risk is about 0.5% to 2%. 12% prevalence of left-sided obstructive lesions in 1st degree relatives. 15-30% incidence of genetic syndromes and extracardiac anomalies in patients w/HLHS. Genetic markers: dHAND, HRT1, HRT2, NOTCH.
Moss & Adams, 2008.
PATHOPHYSIOLOGY
Cardiac development: Flow begets growth. Altered flow through the left side of the heart:
Reduced/altered flow across the foramen ovale. Aortic or mitral obstruction.
Unknown Congenital Heart Defect Normal pregnancy, labor and delivery Clinically doing okay until the PDA closes ** Cyanosis that does not improve with oxygen Many have no other obvious anomalies
DUCTAL-DEPENDENT LESION
PDA needed to:
Provide systemic perfusion
HLHS **
Pulmonary atresia
Hyperoxitest
ABG is measured on room air. Patient is placed on 100% oxygen (intubated) for 10-15 minutes, then ABG is repeated.
If problem is respiratory (i.e. hypoventilation), then PaO2 improves (usually above 200mmHg). If problem is cardiac (i.e. right-to-left intracardiac shunt), there is little improvement of PaO2. Primary pulmonary hypertension may also result in little improvement of PaO2. (Oxygen may hasten closure of PDA!)
Positive Hyperoxitest
Seriously consider initiation of prostaglandin (PGE) at a low dose (0.03 mcg/kg/min) until diagnosis is confirmed.
Initial Assessment
ALWAYS
A - Airway
B - breathing C circulation CXR and ECG usually not very helpful in Dx.
Physical Findings
Comfortable or in distress?
Cyanosis w/out respiratory distress is cardiac until proven otherwise
Pallor
Vasoconstriction from circulatory shock
Respiratory Status
Tachypnea but with minimal distresscardiac until proven otherwise.
Respiratory Status
Respiratory distress
Inability of the respiratory system to compensate for the metabolic acidosis
Concurrent respiratory disease Unrelenting metabolic acidosis - decreased cardiac function Exhaustion
Assisted Ventilation
Intubate if:
Impending respiratory failure Potentially not necessary to intubate just for PGE therapy if ground transport Intubate for air transport in PGE dependent babies
Assisted Ventilation
Ventilation strategy
Volume ventilation if possible to maintain consistent minute ventilation in the face of changing lung compliance Bigger tidal volumes compared to premature newborns (10 cc/kg); lower rates
No need to over-ventilate
40/40/40 club
Blood Gases
Arterial
PH PO2 PCO2 accurate accurate accurate
Capillary Venous
accurate lower invariable lower accurate higher
HCO3 (calculated)
accurate
accurate
accurate
Oxygen
Oxygen is a drug - use it with respect
Saturation Monitoring
Oxygen saturation reflects tissue oxygenation and usually does not correlate with PO2. With pulmonary hypertension will see differential cyanosis - shunts right to left across the PDA. The number is not as important as the patient.
Prostaglandin Infusion
Purpose is to open the PDA if a ductal dependent lesion is suspected Can be initiated before a definitive diagnosis is established Need a secure IV (PIV, PIC, or UVC-central or in the liver)
Prostaglandins continued
Side effects Apnea - be prepared to intubate Fever Hypotension - have volume and inotropes available Flushing
Access
Umbilical is preferred in a newborn
UVC even if in suboptimal position
UAC
Fluid Resuscitation
Needed if poorly perfused 5% albumin bolus (5-10 cc/kg) Watch for and treat hypoglycemia - stress causes epinephrine release which increases utilization of glucose. PRBC to treat anemia - optimize oxygen carrying capacity.
Hypotension
Check ionized calcium
Treat with 50-100mg/kg calcium gluconate or 10 mg/kg calcium chloride via central access
Dopamine Epinephrine
Metabolic Acidosis
Treat metabolic acidosis aggressively (base deficit < -3) 1 meq/kg Na bicarbonate Repeat blood gas
Other Systems
Renal function
Urine output BUN/Cr Renal ultrasound
Genetics
Head ultrasound
Fetal Diagnosis
Fetal Studies
Hornberger, 1995: 21 fetuses with prenatal echos that show left-sided obstruction (small mitral valve & ascending aorta) developed HLHS. Critical aortic stenosis decreased blood flow through left heart LV dilation & dysfunction endocardial fibroelastosis (EFE) backwards flow across PFO LV stops growing & eventually shrinks
HLHS
Case Presentation
Term infant born via SVD Uncomplicated labor and delivery APGARs of 8 at 1min., 9 at 5min. Tachypnea noted at 12hrs of life.
Case Presentation
Airway-Breathing-Circulation
Respiratory rate (60-90 bpm)
Work of breathing (no retractions) Saturations (80%) Warm extremities; good cap refill
Case Presentation
No obvious dysmorphic features.
More Cardiac Exam Findings: No murmur. Single second heart sound (S2). Hyperdynamic precordium.
Case Presentation
Urgent Cardiology Consult Cardiac History & Physical Echocardiogram
Echocardiogram HLHS
echo
Case Presentation
BUT:
No beds available immediately
Case Presentation
Intravenous access
UVC (double lumen)
Case Presentation
Prostaglandins
0.03 mcg/kg/min
Side effects
Apnea Options ?
Intubate vs nasal cannula air
Case Presentation
Labs
Arterial (or venous) blood gas Electrolytes (normalize) CBC LFT Genetics Lactic acid
Case Presentation
R/O Sepsis
If no clinical suspicion or maternal indicators no need to start antibiotics
Follow ABG frequently (Q 4 hrs) Monitor urine output Monitor for acidosis Watch for hypotension
Blood Pressure
Blood pressure - systolic and diastolic blood pressures are equally importantnot just mean!!
Coronary flow to heart dependant on diastolic BP
Case Presentation
Saturations 95% pO2 50 Decreased urine output Metabolic acidosis Rising lactic acid Whats going on?!?
Chest X-Ray
Case Presentation
Pulmonary Over Circulation with systemic compromise
Intubate/hypoventilate CO2
Case Presentation
Y- tube Physiology:
To Lungs
Pulmonary Resistance Lowered by: - Oxygen - Prostaglandin - Resp alkalosis Raised by: - PPV - Hypoxia - Resp acidosis
To Body
Systemic Resistance Raised by:
- Dopamine
- Epinephrine
Monitoring Innovations
Pulmonary Atresia
To Lungs
To Body
Cardiac Transplant
Fairly good quality of life as transplant recipient (have structurally normal heart). Obstacles:
Availability of donor heart (approximately 25-30% die awaiting transplant). Life-long immunosuppression & risk of infection/CA. Usual cause of death/organ death: coronary vasculopathy. Survival: 84% at 1 yr, 76% at 5 yrs., 70% at 7 yrs. Organ survival MUCH reduced w/subsequent transplants.
D. Fontan repair (IVC to PA) - Relieve volume load to RV - Venous blood totally bypasses heart (sats 100%)
Norwood (Stage I)
HLHS Survival
Standard Risk (i.e. no genetic or extracardiac issues)
1 month 85% 1 year 80% 5 year 73%
Higher Risk
1 month 61%
1 year 20%
Fetal Intervention
VERY small balloon catheter is inserted via mothers abdomen, across uterus, through fetal heart across aortic valve. Fetal aortic valvuloplasty is performed. Marginal success with select patients
Must have diagnosis in early 2nd trimester Absence of genetic or extracardiac anomalies Early stage of critical aortic stenosis (LV is dilated with some preserved function, but not yet involuted) Favorable maternal habitus
As we age, the ventricular EDP rises. In Fontan patients, the CVP must exceed the EDP. Eventually, the EDP will rise to an intolerable level.
Comfort Care/Hospice
Why is it a viable option in 2010?
The Fontan is doomed to fail. Dr. Reddington, ACC 2003
Fontan patients will develop protein-losing enteropathy, ventricular dysfunction, hypoxemia, thromboembolism, arrhythmias and liver failure.
Summary
HLHS is universally lethal w/out treatment. A patent foramen ovale & ductus arteriosus are necessary for survival.